Stroke prevention in patients with non-valvular atrial fibrillation


Clinical trials comparing antithrombotic therapy with placebo have shown that Warfarin ( Coumadin ) reduces the risk of stroke by 62%, and that Acetylsalicylic acid ( ASA, Aspirin ) alone reduces the risk by 22%.

In high-risk patients, Warfarin is superior to Acetylsalicylic acid in preventing strokes, with a relative risk reduction of 36%.

Ximelagatran ( Exanta ), an oral direct thrombin inhibitor, was found to be as effective as vitamin K antagonists in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.

The ACTIVE-W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has shown that Warfarin is superior to platelet therapy ( Plavix plus Aspirin ) in the prevention of embolic events.

Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs ( sartans ) are promising in atrial fibrillation through cardiac remodelling.

Preliminary studies have shown that statins could interfere with the risk of recurrence of atrial fibrillation after electrical cardioversion.

Source: Expert Opinion on Pharmacotherapy, 2006


XagenaMedicine_2006



Indietro

Altri articoli

Edoxaban ( Lixiana ) in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in...


The European Society of Cardiology ( ESC ) has recommended uninterrupted anticoagulation with vitamin K antagonists during ablation and device...


Controversy persists over statins and risk of intracerebral hemorrhage. Researchers have determined associations of premorbid lipid-lowering therapy and outcomes among...


The results from two analyses of the GLORIA-AF Registry Program examining the use of antithrombotic treatment to reduce the risk...


Even a single additional stroke risk factor in patients with atrial fibrillation may confer a risk of stroke. However, there...


ESC Guidelines recommended for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention ( PCI...


Venous and arterial thromboses have been regarded for many years as two different diseases requiring anticoagulant or antiplatelet treatment, respectively....


Final data from a phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic events ( VTE ) in patients...


Women suffer more disabling strokes than men and need to become better aware of their unique risk factors, according to...


For patients with atrial fibrillation or atrial flutter of 48-hour duration or longer, or when the duration of atrial fibrillation...